PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-50.78%
Both companies reducing R&D. Martin Whitman would check industry innovation trends.
-4.70%
G&A reduction while AGEN shows 21.16% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-40.44%
Operating expenses reduction while AGEN shows 22.24% growth. Joel Greenblatt would examine advantage.
-35.51%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
0.99%
D&A growth while AGEN reduces D&A. John Neff would investigate differences.
41.12%
EBITDA growth exceeding 1.5x AGEN's 18.76%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
40.44%
Operating income growth exceeding 1.5x AGEN's 17.80%. David Dodd would verify competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-17.42%
Other expenses reduction while AGEN shows 40.15% growth. Joel Greenblatt would examine advantage.
42.50%
Pre-tax income growth 1.25-1.5x AGEN's 29.55%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.50%
Net income growth 1.25-1.5x AGEN's 30.92%. Bruce Berkowitz would examine sustainability.
No Data
No Data available this quarter, please select a different quarter.
40.54%
EPS growth 1.25-1.5x AGEN's 30.52%. Bruce Berkowitz would examine sustainability.
40.54%
Diluted EPS growth 1.25-1.5x AGEN's 30.52%. Bruce Berkowitz would examine sustainability.
0.40%
Share count reduction exceeding 1.5x AGEN's 4.44%. David Dodd would verify capital allocation.
0.40%
Diluted share reduction exceeding 1.5x AGEN's 4.44%. David Dodd would verify capital allocation.